Answers are grounded in this paper and cite their sources.
In this small set of randomised high-risk individuals, we did not demonstrate a protective effect of atorvastatin on arthritis development. The main reason for the low inclusion was unwillingness to participate; this may also impede other RA prevention trials. Further research to investigate and solve barriers for prevention trial participation is needed.
No takes yet. Share an insight, caveat, or question.
Boheemen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: